Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

CRISPR genomic editing to obtain more productive and nutritive plant varieties

New study by the IBMCP of the UPV university facilitates the use of the CRISPR genomic editing technique on plants.

8 Feb 2021

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

The phase 3 human trial is the last stage of clinical evaluation, showing how effective and safe a drug or vaccine is. In this case, the Gam- Sputnik V showed a consistent strong protective effect across all participant age groups.

3 Feb 2021

COVID-19 vaccine should be recommended to patients with Parkinson’s disease, experts say

Patients with Parkinson's disease (PD) and healthcare professionals caring for them have expressed concerns about the COVID-19 vaccine's efficacy and safety in the specific context of PD and its symptomatic treatment.

3 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021

What do we know about the SARS-CoV-2 vaccines so far?

A new study surveys what we know so far about SARS-CoV-2 vaccine candidates from advanced clinical trials.

27 Jan 2021

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic.

14 Jan 2021

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.

14 Jan 2021

Atmospheric particulate matter may influence the transmission and evolution of SARS-CoV-2

A recent study conducted at the University of Malta Medical School, Malta, has revealed that a drop in the level of particulate matter 2.5 (PM2.5), which are airborne pollutant particles with a diameter of 2.5 micrometer, in the atmosphere due to lockdown is associated with the arrival of a newer variant of SARS-CoV-2, which has eventually displaced the original virus after lockdown.

12 Jan 2021

Gene therapy can effectively treat mice with tuberous sclerosis complex, shows study

Patients with tuberous sclerosis complex, a genetic disorder characterized by the growth of noncancerous tumors in multiple organs of the body, have limited treatment options.

8 Jan 2021

Thermo Fisher announces construction of new cGMP plasmid DNA manufacturing facility

Thermo Fisher Scientific, the world leader in serving science, today announced the construction of a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif.

From Thermo Fisher Scientific Inc. 18 Dec 2020

New data shows encouraging results for patients with neuro-degenerative blinding eye disease

New data published in the Journal Science Translational Medicine shows encouraging results in a worldwide clinical trial for patients diagnosed with the neuro-degenerative blinding eye disease; Leber Hereditary Optic Neuropathy (LHON.)

16 Dec 2020

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

First full results from interim analysis confirm that the Oxford COVID-19 vaccine (AZD1222) has an acceptable safety profile and is efficacious against symptomatic COVID-19 disease, with no hospitalizations or severe disease reported in the COVID-19 vaccine group so far.

9 Dec 2020

A new potential COVID-19 vaccine candidate: YF-S0

A recent study published in the journal Nature describes the safety and efficacy of a live-attenuated yellow fever 17D (YF17D) vector-based vaccine candidate expressing a non-cleavable form of the spike protein of severe acute respiratory coronavirus 2 (SARS-CoV2).

2 Dec 2020

Genethon to start international clinical trial for treatment of Duchenne muscular dystrophy

Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM, the French National Agency for Medicines and Health Products Safety, to start in France a multicentre international clinical trial for the treatment of Duchenne muscular dystrophy with product GNT 004.

2 Dec 2020

Oxford University and AstraZeneca release their COVID-19 vaccine results

AstraZeneca and the University of Oxford have just released their results from its interim analysis of AZD1222, a vaccine being trialed to prevent COVID-19.

From AstraZeneca 23 Nov 2020

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

A team of scientists from the University of Oxford, UK, has revealed that site-specific glycosylation differs between spike proteins derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a viral vector-based vaccine candidate.

18 Nov 2020

Repairing brain damage caused by MS

Neurological symptoms as a result of Multiple Sclerosis (MS), such as loss of cognitive or motor function, lead to a great many problems for over 2.5 million people worldwide.

10 Nov 2020

UH and CWRU announce Phase 3 trial of Astrazeneca's investigational COVID-19 vaccine

University Hospitals and Case Western Reserve University announced today that UH Cleveland Medical Center has been selected as a clinical trial site for the Phase 3 global study of an investigational vaccine against SARS-CoV-2, sponsored by AstraZeneca.

29 Oct 2020

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

A recent study published on the preprint server bioRxiv* in October 2020 reports the development of a novel vaccine based on a simian adenoviral vector obtained from a group C gorilla isolate called GRAd32. This could help speed up vaccine development.

26 Oct 2020

Viral Vector News and Research

Further Reading

CRISPR genomic editing to obtain more productive and nutritive plant varieties

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

COVID-19 vaccine should be recommended to patients with Parkinson’s disease, experts say

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

What do we know about the SARS-CoV-2 vaccines so far?

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

Atmospheric particulate matter may influence the transmission and evolution of SARS-CoV-2

Gene therapy can effectively treat mice with tuberous sclerosis complex, shows study

Thermo Fisher announces construction of new cGMP plasmid DNA manufacturing facility

New data shows encouraging results for patients with neuro-degenerative blinding eye disease

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

A new potential COVID-19 vaccine candidate: YF-S0

Genethon to start international clinical trial for treatment of Duchenne muscular dystrophy

Oxford University and AstraZeneca release their COVID-19 vaccine results

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

Repairing brain damage caused by MS

UH and CWRU announce Phase 3 trial of Astrazeneca's investigational COVID-19 vaccine

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

One Health, One Mission: The World Organisation for Animal Health on the AMR Frontline

Uniting Against Resistance: The World Health Organization for World Antimicrobial Awareness Week 2023

Tackling Antimicrobial Resistance: A Conversation with Dr. Beverley Isherwood

Latest Life Science News